Alexandra Gerlach, Associate Editor

Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.

Artificial intelligence (AI) models enhance cancer cachexia detection, improving accuracy in predicting muscle atrophy and patient outcomes through advanced biomarker analysis.

Explore the latest advancements in chronic lymphocytic leukemia treatment, focusing on BTK and BCL2 inhibitors, monoclonal antibodies, and patient management strategies.

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

Study shows a significant decline in breast cancer mortality across multiple subtypes.

Acneiform rash is a common adverse effect of EGFR-targeting therapies.

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.

The study found that 4 weeks was the ideal time point to test for cTDNA.

This alternative to IV infusion reduces patient treatment times and eases providers’ operational burdens.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

The combination yielded superior progression-free (PFS) survival compared with standard of care.

Patients in both arms achieved statistically significant rates of compliance up to 97%.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.

Thrombosis occurs in approximately 20% of myeloproliferative neoplasms.

Experts attribute the increase of pertussis cases to declining DTaP vaccination rates.

The meaningful results were reported in the DESTINY-Breast09 trial.

Cases have been confirmed in Mexico and Canada.

Real-world data support momelotinib as an effective and well-tolerated treatment for myelofibrosis-related anemia.

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.

Undetectable minimal residual disease rates improved with ongoing therapy.

The data showed improvements in overall response rates, progression-free survival, and duration of response.

Iman Ahmed, PharmD, BCOP, shared key insights about how social determinants of health impact treatment access and outcomes for patients with leukemia.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, shared insight from the HOPA Annual Meeting 2025.

Arefa Bacchus, PharmD, shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.